Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.

ABSTRACT:

Objectives

To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease.

Patients and methods

We performed a retrospective cohort study collecting clinicopathological, treatment and outcomes data for patients with aUC receiving ICIs across 25 institutions. We compared outcomes (observed response rate [ORR], progression-free survival [PFS], overall survival [OS]) between patients with vs without prior RS, and by type of prior locoregional treatment (RS vs RT vs no locoregional treatment). Patients with de novo advanced disease were excluded. Analysis was stratified by treatm

SUBMITTER: Makrakis D 

PROVIDER: S-EPMC10257152 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature